Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 175 participants.

Also called NCT02522481

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 175 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02522481
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Germany, Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02522481. Allocation not applicable; no masking; primary purpose diagnostic. Start 2015-09-24 (actual); primary completion 2017-11-07 (actual). Results posted on 2020-08-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141
Intervention (Drug)
Lumason
Lead sponsor
Bracco Diagnostics, Inc (class: industry)

Record details

Record id
cardio:ct-nct02522481
Content hash
c5d1de54e76161f79838d510676b5260687b6c8f6fb906ae93d1f00211c3f0fe